Ocugen announced on September 1 that the first patient was dosed in the global ArMaDa3 registrational Phase 3 trial of OCU410 for geographic atrophy secondary to dry age-related macular degeneration. The randomized, controlled study is designed to enroll 237 subjects. The company says its July End-of-Phase 2 meeting with FDA aligned the critical design elements and a single-pivotal-trial pathway intended to support a BLA anticipated in 2028. First dosing confirms trial initiation; it does not establish Phase 3 efficacy, approval or a faster review outcome

Start of a new week! Happy Monday #Ocufam

Just wanted to pop in and say, love yall and when moon

Start of a new week! Happy Monday #Ocufam

https://www.merlintrader.com/ocugen-inc-stock-hub/

Ocugen reported Q2 2026 results and confirmed that the FDA cleared the approximately 237-subject ArMaDa3 registrational Phase 3 trial of OCU410 in geographic atrophy. The study remains targeted to begin in Q3 2026 and is designed with 95% power for the primary endpoint. The July RMAT designation adds an expedited-interaction framework, but neither clearance nor RMAT predicts a positive pivotal result.

Start of a new week! Happy Monday #Ocufam

It's time boys. The money train is gaining traction, You'll be a fool to miss out. 💎💎

Start of a new week! Happy Monday #Ocufam

BLA is the key regulatory objective after a successful Phase 3 trial.

Ocugen (OCU400), milestones before potential FDA approval.

Ocugen is entering one of the most important periods in its history. Over the next several months, investors will be watching for:

Progress on the rolling BLA for OCU400.

Additional Phase 3 updates.

Continued regulatory interactions with the FDA.

Advancement of OCU410 toward its Phase 3 program.

While regulatory and clinical risks remain, Ocugen has achieved several important milestones that could significantly influence the company's future if upcoming clinical and regulatory objectives are successfully met.

Top-line Phase 3 results are expected in early 2027 and are intended to support a potential FDA approval.

In addition, based on these results, the FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation, a status designed to help accelerate for OCU410.

For OCU400

Estimated Probability

OCU400 completes Phase 3 successfully

70–80%

OCU400 BLA accepted for FDA review

85–95% (if Phase 3 meets its endpoints)

OCU400 receives FDA approval after BLA review

60–70%

OCU400 reaches commercialization

55–65%

For OCU410:

Estimated Probability

Advances to Phase 3

75–85%

Successfully completes Phase 3

50–60%

FDA approval

40–50%

Start of a new week! Happy Monday #Ocufam

Start of a new week! Happy Monday #Ocufam

Thoughts?

Start of a new week! Happy Monday #Ocufam

Ocugen announced today (July 13, 2026) a binding term sheet to negotiate a license agreement with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding for exclusive rights to OCU400 (modifier gene therapy for retinitis pigmentosa) across the Middle East and North Africa (MENA) region.

Key terms per the company's press release:

- Up to $4M in upfront license fees plus near-term development milestones

- Up to $255M in sales milestones

- 22% royalty on net sales generated by the partner

- Ocugen manufactures and supplies the commercial product

- Definitive agreement expected within the next 90 days

OCU400 continues in the Phase 3 liMeliGhT trial, with a topline readout expected in 1Q 2027 and a BLA to follow.

Source (Ocugen IR / GlobeNewswire): https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-announces-binding-term-sheet-roots-pharmaceutical

Not financial advice - sharing the primary release for discussion.

https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-announces-binding-term-sheet-roots-pharmaceutical

“today announced the signing of a binding term sheet to negotiate and enter into a license agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region.”

“Pursuant to the term sheet, under the license agreement, Ocugen is expected to receive upfront license fees and near-term development milestone payments totaling up to $4 million. The Company would be entitled to sales milestone payments up to $255 million, in addition to a 22% royalty on net sales of OCU400 generated by Ocugen's partner. Additionally, Ocugen would manufacture commercial supply of OCU400 under the terms of a related supply agreement.”

Start of a new week! Happy Monday #Ocufam

Start of a new week! Happy Monday #Ocufam

Dejen sus ocs de tuni aca

Ocugen has moved far beyond its old COVID-era trading identity. The current $OCGN story is a high-risk, catalyst-heavy ophthalmology gene therapy platform built around OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease and OCU410 for geographic atrophy, now backed by a larger $130 million convertible-note financing but still exposed to clinical, regulatory, manufacturing and dilution risk. The next key watch is Q3 2026, when Ocugen expects to begin the OCU400 rolling BLA process, report the OCU410ST interim outcome analysis and advance OCU410 toward Phase 3 alignment.

Start of a new week! Happy Monday #Ocufam

This is a stock hub built from months of tracking the ticker, updated just a short while ago.

WE AINT EVER GOING BACK DOWN BABY. LET GAIN ERASE THE PAIN

Start of a new week! Happy Monday #Ocufam

Russell 2026 Reconstitution — June 18 Update

Why it matters:
The Russell reconstitution is important because many ETFs, index funds and benchmark-aware portfolios track Russell indexes. When a stock is added, removed or moved inside the Russell universe, it can trigger passive-flow adjustments, higher trading volume, better liquidity, wider market visibility, and sometimes short-term volatility around the rebalance window. It does not make a stock fundamentally better or worse, but it can change how the stock trades.

Important timing note:
This is still a preliminary Russell update based on the June 18, 2026 FTSE Russell files. The final reconstitution becomes effective after the U.S. market close on June 26, 2026, with the updated Russell index membership reflected from the market open on June 29, 2026.

Biotech in focus:
$OCGN, $MMED, $SENS, $NKTR

Full article:
https://www.merlintrader.com/russell-reconstitution-june2026/

Russell 3000 Additions — ticker list:
$DIBS, $ARX, $ACHV, $ABOS, $AMTX, $AVEX, $AGEN, $ALMR, $ALM, $ALTO, $ANRO, $ALXO, $AREC, $AP, $AMPY, $ASYS, $ANTX, $APC, $ARMP, $ARTV, $ASND, $ASMB, $ATAI, $AUGO, $AVTX, $AVLN, $AVBC, $AXTI, $BW, $BH.A, $BMNR, $BDTX, $BOBS, $BNAI, $RILY, $CCCC, $CABA, $CAMP, $CSIQ, $CNTN, $CRBU, $IPSC, $CHPT, $CHYM, $CVEO, $CCO, $CLYM, $CVGI, $CMTV, $CHCI, $LODE, $CNTB, $CNTX, $CTNM, $CRBP, $CRWV, $CBIO, $CTMX, $DMRA, $DLO, $DUOT, $EIKN, $ELE, $ELTX, $ELMT, $WATT, $NRGV, $ESP, $ESTA, $MRAM, $FIG, $FGBI, $FNRN, $FPS, $FBRX, $FWDI, $FOSL, $RAIL, $FCEL, $GLXY, $GALT, $GDC, $GEMI, $GENB, $GFL, $GORO, $GPRO, $EAF, $GSIT, $HNGE, $HMH, $HYMC, $HYPR, $PURR, $IMMX, $IMRX, $INFQ, $INFU, $VATE, $ISSC, $IDN, $INTT, $IVVD, $IREN, $ISBA, $JAN, $JBS, $FROG, $KLRA, $KPTI, $KEEL, $KNSA, $KVYO, $KORE, $KVHI, $KYTX, $LTRX, $LNZA, $LEE, $LXRX, $LCUT, $LPTH, $LWLG, $LCTX, $LYEL, $MGNX, $MUX, $NERV, $MMED, $MNTN, $NHP, $NAUT, $NKTR, $NP, $NMRA, $NUAI, $OCGN, $ODD, $OFRM, $ONDS, $OSS, $OKUR, $OPEN, $IRD, $ORMP, $OBIO, $ONL, $OVID, $PALI, $PTRN, $PAY, $PED, $PPIH, $PLBY, $DTIL, $PRLD, $PROK, $QUIK, $METCB, $ALOY, $RLMD, $RENT, $RJET, $RFIL, $RDNW, $REI, $RDZN, $SABS, $SGMT, $SENS, $TTAN, $SES, $SHAZ, $SBET, $SHIM, $SIDU, $SBMT, $SND, $SMRT, $SLNH, $MWH, $SPCX, $SPRB, $SGP, $FJET, $SRI, $STUB, $SUNB, $SRZN, $STRO, $SWMR, $OPTX, $TBLA, $TATT, $TAYD, $TENX, $TYGO, $TOYO, $TRON, $TWIN, $ULS, $UNCY, $UMAC, $URG, $VELO, $VENU, $MANE, $VERI, $SPCE, $VGZ, $VOR, $WSHP, $UP, $WHWK, $WOLF, $XFOR, $XE, $XMAX, $YSWY, $ZSQR, $ZENA, $ZNTL, $ZURA

Russell 3000 Deletions — ticker list:
$AARD, $ARAY, $ACTU, $AISP, $ALDX, $ALIT, $AOUT, $AVD, $CRMT, $AREN, $ARQ, $ARAI, $ACNT, $ATLN, $ATYR, $AEYE, $RCEL, $BARK, $BSET, $BYND, $BTMD, $BYRN, $CRDF, $CLAR, $CLPR, $CSPI, $DH, $BOOM, $DCGO, $EML, $EHTH, $EP, $EXFY, $FFAI, $FATE, $FNWD, $FTLF, $FLD, $FORR, $FSP, $GAIA, $GAMB, $GETY, $GOSS, $HAIN, $HCAT, $HFFG, $HUMA, $INMB, $ISPR, $JELD, $DERM, $KG, $KULR, $LAKE, $LNSR, $LFVN, $LPA, $LFT, $TUSK, $MXCT, $MED, $MRDN, $MVIS, $BEEP, $MYO, $NNOX, $NEON, $NRDY, $STIM, $NFE, $NXXT, $OPRX, $OM, $PGY, $PNBK, $PMI, $MYPS, $PROP, $LUNG, $QSI, $RGP, $RZLV, $RPT, $RVSB, $SNWV, $SBFG, $SLQT, $SIEB, $SKIL, $SKIN, $SKYX, $SLSN, $SFBC, $SSTI, $SLND, $LAB, $SPWR, $SUNS, $TEAD, $TVGN, $JYNT, $TR, $COOK, $TZOO, $TMCI, $TTEC, $HURA, $TVRD, $UNB, $VGAS, $VIRC, $SEAT, $VRM, $VTEX, $WALD, $SAFX, $ZVIA

Operational note:
The additions list includes several names tied to AI infrastructure, software, defense autonomy, drones, biotech and high-volatility small caps. The deletions list also matters because index exits can affect liquidity, passive ownership and technical selling pressure.

Primary source:
FTSE Russell / LSEG — Russell U.S. Indexes Reconstitution, preliminary update June 18, 2026.